JP2021506769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506769A5 JP2021506769A5 JP2020531748A JP2020531748A JP2021506769A5 JP 2021506769 A5 JP2021506769 A5 JP 2021506769A5 JP 2020531748 A JP2020531748 A JP 2020531748A JP 2020531748 A JP2020531748 A JP 2020531748A JP 2021506769 A5 JP2021506769 A5 JP 2021506769A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- gram
- lytic
- fragment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 230000002101 lytic effect Effects 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 241000894006 Bacteria Species 0.000 claims 17
- 239000006166 lysate Substances 0.000 claims 15
- 241000894007 species Species 0.000 claims 12
- 230000001420 bacteriolytic effect Effects 0.000 claims 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 8
- 230000001320 lysogenic effect Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 2
- 241000589516 Pseudomonas Species 0.000 claims 2
- 229960004682 cefoperazone Drugs 0.000 claims 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 241000588923 Citrobacter Species 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000589602 Francisella tularensis Species 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- -1 aminoglycoside Chemical compound 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229960000895 doripenem Drugs 0.000 claims 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940118764 francisella tularensis Drugs 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 229960005266 polymyxin b Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960004659 ticarcillin Drugs 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023181425A JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597577P | 2017-12-12 | 2017-12-12 | |
| US62/597,577 | 2017-12-12 | ||
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US62/721,969 | 2018-08-23 | ||
| PCT/US2018/065265 WO2019118632A1 (en) | 2017-12-12 | 2018-12-12 | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181425A Division JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506769A JP2021506769A (ja) | 2021-02-22 |
| JP2021506769A5 true JP2021506769A5 (https=) | 2022-01-06 |
Family
ID=66819724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Pending JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
| JP2023181425A Active JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181425A Active JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12121568B2 (https=) |
| EP (1) | EP3723789A4 (https=) |
| JP (2) | JP2021506769A (https=) |
| KR (1) | KR20200098615A (https=) |
| CN (1) | CN111971058A (https=) |
| AU (1) | AU2018384790C1 (https=) |
| BR (1) | BR112020011433A2 (https=) |
| CA (1) | CA3085644A1 (https=) |
| IL (2) | IL303122A (https=) |
| MX (1) | MX2020006098A (https=) |
| WO (1) | WO2019118632A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| WO2019126670A1 (en) * | 2017-12-22 | 2019-06-27 | The Rockefeller University | Recombinant pseudomonas aeruginosa lysins |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US10988520B2 (en) | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3840771A4 (en) * | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| CN114040773A (zh) * | 2019-04-05 | 2022-02-11 | 康特拉费克特公司 | 在存在人血清的情况下对铜绿假单胞菌具有杀菌活性的溶素及其衍生物 |
| KR102225240B1 (ko) * | 2019-07-03 | 2021-03-10 | 경북대학교 산학협력단 | 다제내성 병원성 세균을 효과적으로 사멸시키는 재조합 항균 단백질 Ablysin의 용도 |
| EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corporation | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
| US20250324979A1 (en) * | 2021-09-03 | 2025-10-23 | Alexandre Ismail | LysECD7 VARIANTS AND METHODS OF USING THE SAME |
| CN114410670B (zh) * | 2022-01-29 | 2024-01-23 | 福建医科大学附属口腔医院 | 一种溶菌酶及其在口腔护理用品中的应用 |
| CN117660413B (zh) * | 2023-12-15 | 2024-06-07 | 华南理工大学 | 一种内溶素Lys009及其工程改造和应用 |
| CN120173923A (zh) * | 2025-05-08 | 2025-06-20 | 浙江大学 | 与PeiR裂解酶高维特征同源的产甲烷菌裂解酶及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| AU2010211456B2 (en) | 2009-02-06 | 2016-05-26 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
| CA2780079A1 (en) | 2009-11-18 | 2011-05-26 | Basf Plant Science Company Gmbh | Process for the production of fine chemicals |
| SG184836A1 (en) | 2010-04-27 | 2012-11-29 | Lysando Ag | Method of reducing biofilms |
| GB201018518D0 (en) | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| DK2699253T3 (en) | 2011-04-21 | 2018-07-16 | Univ Rockefeller | STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES |
| WO2015070912A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
| WO2015200783A2 (en) | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| EP4115897A1 (en) * | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| CN108103050A (zh) | 2018-02-11 | 2018-06-01 | 中国医药集团总公司四川抗菌素工业研究所 | 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用 |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3840771A4 (en) | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
-
2018
- 2018-12-12 WO PCT/US2018/065265 patent/WO2019118632A1/en not_active Ceased
- 2018-12-12 IL IL303122A patent/IL303122A/en unknown
- 2018-12-12 MX MX2020006098A patent/MX2020006098A/es unknown
- 2018-12-12 JP JP2020531748A patent/JP2021506769A/ja active Pending
- 2018-12-12 AU AU2018384790A patent/AU2018384790C1/en active Active
- 2018-12-12 IL IL275060A patent/IL275060B2/en unknown
- 2018-12-12 KR KR1020207020090A patent/KR20200098615A/ko not_active Ceased
- 2018-12-12 EP EP18889220.2A patent/EP3723789A4/en not_active Withdrawn
- 2018-12-12 CN CN201880089186.9A patent/CN111971058A/zh active Pending
- 2018-12-12 BR BR112020011433-2A patent/BR112020011433A2/pt not_active Application Discontinuation
- 2018-12-12 US US16/772,001 patent/US12121568B2/en active Active
- 2018-12-12 CA CA3085644A patent/CA3085644A1/en active Pending
-
2023
- 2023-10-20 JP JP2023181425A patent/JP7646237B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506769A5 (https=) | ||
| JP2021519083A5 (https=) | ||
| IL277119B2 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| JP2024010053A5 (https=) | ||
| RU2018107245A (ru) | Полипептиды лизина, активные против грамотрицательных бактерий | |
| Łusiak-Szelachowska et al. | Bacteriophages and lysins in biofilm control | |
| JPWO2019191633A5 (https=) | ||
| JP2021533728A5 (https=) | ||
| Shahrour et al. | AMPs as anti-biofilm agents for human therapy and prophylaxis | |
| IL313959A (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| Simoes et al. | Novel antibacterial agents: an emergent need to win the battle against infections | |
| EP3164146B1 (en) | Acinetobacter lysins | |
| MX2020006098A (es) | Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. | |
| JP2021519311A5 (https=) | ||
| CN112218659A (zh) | 用于治疗葡萄球菌感染的治疗性噬菌体组合物 | |
| Zhang et al. | In Vitro Study of Bacteriophage AB3 Endolysin LysAB3 Activity Against Acinetobacter baumannii Biofilm and Biofilm-Bound A. baumannii. | |
| RU2020128276A (ru) | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| Kozlovska et al. | The effect of antimicrobial agents on planktonic and biofilm forms of bacteria that are isolated from chronic anal fissures | |
| Ming et al. | The antibacterial effects of antimicrobial peptides OP-145 against clinically isolated multi-resistant strains | |
| JP2021508501A (ja) | Ｐｓｅｕｄｏｍｏｎａｓ感染症を処置するためのバクテリオファージ組成物 | |
| JPWO2020046747A5 (https=) | ||
| JPWO2021180892A5 (https=) | ||
| JPWO2020206327A5 (https=) | ||
| RU2020131450A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий | |
| JPWO2019191598A5 (https=) |